Yanzi MAR, Goicochea MT, Yorio F, et al. - Researchers conducted this retrospective cohort study to characterize patients with chronic headache disorders (CH) and medication overuse headache (MOH) treated with intravenous chlorpromazine (IVC) to see if IVC is an safe and efficacious addition to well‐known treatment strategies for managing CH and MOH. The sample consisted of 35 patients hospitalized to receive treatment for CH in a specialized neurological center in Argentina. MOH was also present in 33 (94%) of the 35 patients. With IVC administration, only minor side effects (mainly drowsiness and symptomatic hypotension) were recorded. Three months after inpatient treatment, headache frequency decreased in 20/34 (59%) patients and the number of ER visits made by these patients dropped from an average of 2.8 in the 3 months prior to hospitalization to 0.7 after it. Pain levels also decreased from a mean of 8 points at admission (in a scale of 1‐10) to 2 points at discharge. There were no significant safety issues with IVC administration in this particular group of inpatients and the study may indicate IVC's effectiveness as an add‐on treatment for CH and MOH.